Equities Analysts Offer Predictions for VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Voyager Therapeutics in a research note issued on Monday, January 13th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($0.98) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $5.73 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.89) per share.

VYGR has been the subject of a number of other reports. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush initiated coverage on Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 target price on the stock. Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $15.97.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $5.28 on Tuesday. Voyager Therapeutics has a 12-month low of $5.14 and a 12-month high of $10.66. The stock has a market capitalization of $288.43 million, a PE ratio of 7.44 and a beta of 0.93. The firm has a 50 day simple moving average of $6.09 and a 200-day simple moving average of $6.80.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the prior year, the firm posted ($0.59) EPS.

Insider Buying and Selling at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its position in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares in the last quarter. Hunter Perkins Capital Management LLC increased its stake in Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after buying an additional 2,025 shares during the period. Empowered Funds LLC lifted its position in Voyager Therapeutics by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after buying an additional 2,278 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Voyager Therapeutics by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock valued at $4,384,000 after buying an additional 2,638 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Voyager Therapeutics by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock valued at $804,000 after acquiring an additional 3,473 shares in the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.